Cherigo Lilia, Lopez Dioxelis, Martinez-Luis Sergio
Department of Organic Chemistry, Chemistry School, Faculty of Natural Sciences, Exact and Technology, University of Panama, Panama City P.O. Box 3366, Panama.
Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, India.
Mar Drugs. 2015 Apr 3;13(4):2010-29. doi: 10.3390/md13042010.
Breast cancer resistance protein (BCRP) is a protein belonging to the ATP-binding cassette (ABC) transporter superfamily that has clinical relevance due to its multi-drug resistance properties in cancer. BCRP can be associated with clinical cancer drug resistance, in particular acute myelogenous or acute lymphocytic leukemias. The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin. The Food and Drugs Administration has already recognized that BCRP is clinically one of the most important drug transporters, mainly because it leads to a reduction of clinical efficacy of various anticancer drugs through its ATP-dependent drug efflux pump function as well as its apparent participation in drug resistance. This review article aims to summarize the different research findings on marine natural products with BCRP inhibiting activity. In this sense, the potential modulation of physiological targets of BCRP by natural or synthetic compounds offers a great possibility for the discovery of new drugs and valuable research tools to recognize the function of the complex ABC-transporters.
乳腺癌耐药蛋白（BCRP）是一种属于ATP结合盒（ABC）转运蛋白超家族的蛋白质，因其在癌症中的多药耐药特性而具有临床相关性。BCRP可与临床癌症耐药相关，尤其是急性髓性白血病或急性淋巴细胞白血病。BCRP的过表达导致对多种化疗药物产生耐药性，如拓扑替康、甲氨蝶呤、米托蒽醌、阿霉素和柔红霉素。美国食品药品监督管理局已经认识到BCRP是临床上最重要的药物转运蛋白之一，主要是因为它通过其ATP依赖性药物外排泵功能以及明显参与耐药性导致各种抗癌药物的临床疗效降低。这篇综述文章旨在总结具有BCRP抑制活性的海洋天然产物的不同研究结果。从这个意义上说，天然或合成化合物对BCRP生理靶点的潜在调节为发现新药和识别复杂ABC转运蛋白功能的有价值研究工具提供了很大可能性。
